Tareen Rahman :
Glaxo SmithKline (GSK), a British multinational pharmaceutical company, is currently looking for a long-term future investment plan in Bangladesh, Ramil Burden, its Vice President, Developing Countries Asia and External Affairs Africa, has said.
He said GSK is developing a five to ten-year long-term strategic investment plan in the country to continue investment in innovations, research and development and also in the areas of unmet medical needs.
Talking to this reporter on the sidelines of the ‘BRAC Frugal Innovation Forum 2015’ in Savar on Tuesday, the GSK VP said as a global healthcare company, the target of GSK is to get closer to every one and no one can ignore Bangladesh as a growing economy as people here are keen to get better health care.
The plan to establish an Academic Chair at BRAC University in Bangladesh will be supported by GSK and Save the Children, as part of their five-year collaboration to help save the lives of one million of the world’s most vulnerable children.
While commenting on the three days visit to Bangladesh (March 23-26), Ramil said, “Our long-term vision is very positive about Bangladesh as this country is growing very rapidly in market size. Besides, to promote access to healthcare we’re reinvesting 20 per cent of our profits to build healthcare infrastructure by creating frontline health workers at the hard to reach haor areas in the country”.
The ongoing political turmoil and crisis scenario in Bangladesh has made most investors skeptical about investing in a country like Bangladesh. However, he said, “Long term investment decisions should not be based on short-term political crisis.”
“The market size and economy of Bangladesh is growing at a good pace. There is no cause to think negatively about investing in a growing market like Bangladesh. So, we are very positive about Bangladesh. Every country and every market goes through good and bad times. We cannot expect smooth sailing in any country all the time. Some countries have currency risks, some countries have political risks and some have other negative issues,” Ramil added.
Glaxo SmithKline (GSK), the London-based one of the world’s leading research-oriented pharmaceutical and healthcare companies, is committed to improving the quality of human life by making human beings do better, live healthier and longer.
Ramil said GSK has taken the commitment to tackle the three “priority” diseases identified by the World Health Organization (WHO). Those three are : HIV/AIDS, tuberculosis and malaria . GSK does research and develop a broad range of innovative products in three primary areas of pharmaceuticals, vaccines and consumer healthcare globally.
Responding to a question, he said Bangladesh obviously has many challenges and GSK wants to be a part of solutions to these national problems. GSK will invest a huge amount of money to help build the capability of frontline healthcare workers in Bangladesh which is in turn going to help communities get access to better healthcare system.
He also placed importance on public-private partnership (PPP) for better healthcare facilities in Bangladesh. He said, ‘It’s absolutely crucial and essential for us to develop the PPP in medical field in Bangladesh. “This partnership will help bring more benefit for the people of this nation.”
Glaxo SmithKline (GSK), a British multinational pharmaceutical company, is currently looking for a long-term future investment plan in Bangladesh, Ramil Burden, its Vice President, Developing Countries Asia and External Affairs Africa, has said.
He said GSK is developing a five to ten-year long-term strategic investment plan in the country to continue investment in innovations, research and development and also in the areas of unmet medical needs.
Talking to this reporter on the sidelines of the ‘BRAC Frugal Innovation Forum 2015’ in Savar on Tuesday, the GSK VP said as a global healthcare company, the target of GSK is to get closer to every one and no one can ignore Bangladesh as a growing economy as people here are keen to get better health care.
The plan to establish an Academic Chair at BRAC University in Bangladesh will be supported by GSK and Save the Children, as part of their five-year collaboration to help save the lives of one million of the world’s most vulnerable children.
While commenting on the three days visit to Bangladesh (March 23-26), Ramil said, “Our long-term vision is very positive about Bangladesh as this country is growing very rapidly in market size. Besides, to promote access to healthcare we’re reinvesting 20 per cent of our profits to build healthcare infrastructure by creating frontline health workers at the hard to reach haor areas in the country”.
The ongoing political turmoil and crisis scenario in Bangladesh has made most investors skeptical about investing in a country like Bangladesh. However, he said, “Long term investment decisions should not be based on short-term political crisis.”
“The market size and economy of Bangladesh is growing at a good pace. There is no cause to think negatively about investing in a growing market like Bangladesh. So, we are very positive about Bangladesh. Every country and every market goes through good and bad times. We cannot expect smooth sailing in any country all the time. Some countries have currency risks, some countries have political risks and some have other negative issues,” Ramil added.
Glaxo SmithKline (GSK), the London-based one of the world’s leading research-oriented pharmaceutical and healthcare companies, is committed to improving the quality of human life by making human beings do better, live healthier and longer.
Ramil said GSK has taken the commitment to tackle the three “priority” diseases identified by the World Health Organization (WHO). Those three are : HIV/AIDS, tuberculosis and malaria . GSK does research and develop a broad range of innovative products in three primary areas of pharmaceuticals, vaccines and consumer healthcare globally.
Responding to a question, he said Bangladesh obviously has many challenges and GSK wants to be a part of solutions to these national problems. GSK will invest a huge amount of money to help build the capability of frontline healthcare workers in Bangladesh which is in turn going to help communities get access to better healthcare system.
He also placed importance on public-private partnership (PPP) for better healthcare facilities in Bangladesh. He said, ‘It’s absolutely crucial and essential for us to develop the PPP in medical field in Bangladesh. “This partnership will help bring more benefit for the people of this nation.”
